Marburg I Polymorphism of Factor VII–Activating Protease A Prominent Risk Predictor of Carotid Stenosis
Background— Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease “factor seven–activating protease” (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I pol...
Saved in:
Published in | Circulation (New York, N.Y.) Vol. 107; no. 5; pp. 667 - 670 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
11.02.2003
American Heart Association, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0009-7322 1524-4539 1524-4539 |
DOI | 10.1161/01.CIR.0000055189.18831.B1 |
Cover
Abstract | Background—
Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease “factor seven–activating protease” (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis.
Methods and Results—
This analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes.
Conclusions—
In concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis. |
---|---|
AbstractList | Background—
Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease “factor seven–activating protease” (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis.
Methods and Results—
This analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes.
Conclusions—
In concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis. Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease "factor seven-activating protease" (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis.BACKGROUNDAtherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease "factor seven-activating protease" (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis.This analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes.METHODS AND RESULTSThis analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes.In concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis.CONCLUSIONSIn concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis. Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease "factor seven-activating protease" (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis. This analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes. In concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis. BACKGROUND: Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease "factor seven-activating protease" (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis. METHODS AND RESULTS: This analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes. CONCLUSIONS: In concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis. |
Author | Kiechl, Stefan Mair, Artur Weimer, Thomas Santer, Peter Wiedermann, Christian J. Roemisch, Juergen Willeit, Johann |
Author_xml | – sequence: 1 givenname: Johann surname: Willeit fullname: Willeit, Johann organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany – sequence: 2 givenname: Stefan surname: Kiechl fullname: Kiechl, Stefan organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany – sequence: 3 givenname: Thomas surname: Weimer fullname: Weimer, Thomas organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany – sequence: 4 givenname: Artur surname: Mair fullname: Mair, Artur organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany – sequence: 5 givenname: Peter surname: Santer fullname: Santer, Peter organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany – sequence: 6 givenname: Christian J. surname: Wiedermann fullname: Wiedermann, Christian J. organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany – sequence: 7 givenname: Juergen surname: Roemisch fullname: Roemisch, Juergen organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14544080$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/12578864$$D View this record in MEDLINE/PubMed |
BookMark | eNqN0c1O3DAQB3CrApVlyyugCIneEjz-DidgVdpIIFDVcrUcrwNBSbzYSSVufYe-YZ-k3rJoJU74Yln-zWg0_320M_jBIXQEuAAQcIKhWFTfC7w-nIMqC1CKQnEBH9AMOGE547TcQbP0X-aSErKH9mN8TE9BJf-I9oBwqZRgM3R6bUI9hfusym5999z7sHpoY5_5Jrs0dvQhu6uqv7__nNux_WXGdrjPboMfnYnuE9ptTBfdweaeo5-XX34svuVXN1-rxflVbhnQMa9rTEGWDQEmhGRE0MaShi9pyeSyFEsmcMmsw2tNVU2VJLI2SpSOc-YEoXP0-aXvKvinycVR9220ruvM4PwUtaQYS5L6ztHRG_jopzCk2TQBIjlWQiV0uEFT3bulXoW2N-FZv64kgeMNMNGarglmsG3cOsYZwwond_ribPAxBtdsCdbrnDQGnXLS25z0_5z0BaTiszfFth3Tev0wBtN272nxD4T2lmU |
CODEN | CIRCAZ |
CitedBy_id | crossref_primary_10_1096_fj_202200828R crossref_primary_10_1191_1358863x05vm609oa crossref_primary_10_1160_TH17_02_0081 crossref_primary_10_2491_jjsth_21_3 crossref_primary_10_1161_JAHA_120_016445 crossref_primary_10_1007_s11010_019_03501_2 crossref_primary_10_1016_j_thromres_2012_07_023 crossref_primary_10_1038_s41392_021_00802_1 crossref_primary_10_5482_ha_1159 crossref_primary_10_1111_jth_13417 crossref_primary_10_1056_NEJMc1511631 crossref_primary_10_1016_j_jvs_2006_06_016 crossref_primary_10_1016_j_thromres_2010_03_003 crossref_primary_10_1038_s41598_019_55531_x crossref_primary_10_1074_jbc_M112_433029 crossref_primary_10_1515_CCLM_2011_199 crossref_primary_10_1096_fj_03_0898fje crossref_primary_10_1097_MBC_0000000000000640 crossref_primary_10_1378_chest_126_3_suppl_265S crossref_primary_10_1016_j_atherosclerosis_2007_03_042 crossref_primary_10_1093_hmg_ddab124 crossref_primary_10_1182_blood_2004_08_3328 crossref_primary_10_1042_BJ20070166 crossref_primary_10_5551_jat_9589 crossref_primary_10_1016_j_atherosclerosis_2017_08_029 crossref_primary_10_1111_j_1538_7836_2012_04692_x crossref_primary_10_1074_jbc_M610748200 crossref_primary_10_1016_j_thromres_2019_08_016 crossref_primary_10_1160_TH14_06_0519 crossref_primary_10_3109_13697131003597027 crossref_primary_10_1042_BJ20041021 crossref_primary_10_1002_cbic_201900705 crossref_primary_10_1002_prca_201300078 crossref_primary_10_1111_j_1538_7836_2009_03641_x crossref_primary_10_1111_j_1742_4658_2009_07183_x crossref_primary_10_1016_j_bbadis_2018_07_030 crossref_primary_10_1016_j_bbrc_2011_05_030 crossref_primary_10_1111_j_1538_7836_2009_03718_x crossref_primary_10_3390_cells8111396 crossref_primary_10_1016_j_thromres_2008_02_002 crossref_primary_10_1007_s11239_013_0921_0 crossref_primary_10_3389_fneur_2022_1076898 crossref_primary_10_3389_fneur_2023_1174425 crossref_primary_10_4049_jimmunol_1103029 crossref_primary_10_1021_acschembio_2c00538 crossref_primary_10_1084_jem_20052546 crossref_primary_10_1016_j_ejogrb_2012_10_035 crossref_primary_10_1515_CCLM_2008_218 crossref_primary_10_1042_BJ20051563 crossref_primary_10_1016_j_thromres_2012_02_009 crossref_primary_10_1182_blood_2005_02_0576 crossref_primary_10_1016_j_febslet_2009_05_012 crossref_primary_10_1016_j_jhep_2012_09_007 crossref_primary_10_1111_ejn_12830 crossref_primary_10_1177_0268355519881604 crossref_primary_10_1515_CCLM_2010_334 crossref_primary_10_4061_2011_424759 crossref_primary_10_5551_jat_53074 crossref_primary_10_1016_j_molimm_2021_11_019 crossref_primary_10_1111_jth_14258 crossref_primary_10_3390_ijms232213706 crossref_primary_10_1016_j_atherosclerosis_2013_08_007 crossref_primary_10_1016_j_thromres_2020_02_010 crossref_primary_10_1080_1354750X_2018_1434681 crossref_primary_10_1177_1747493016641949 crossref_primary_10_1210_jc_2015_3928 crossref_primary_10_1002_hep_22707 crossref_primary_10_1016_j_thromres_2022_09_027 crossref_primary_10_1042_BJ20061630 crossref_primary_10_5482_ha_1187 crossref_primary_10_1016_j_intimp_2007_10_012 |
Cites_doi | 10.1093/oxfordjournals.jbchem.a021861 10.1182/blood.V96.5.1820 10.1161/atvb.19.6.1491 10.1097/00001721-200201000-00001 10.1093/oxfordjournals.jbchem.a021362 10.1055/s-0037-1614949 10.1161/atvb.20.2.529 10.1515/BC.2002.121 10.1161/atvb.19.6.1484 |
ContentType | Journal Article |
Copyright | 2003 INIST-CNRS Copyright American Heart Association, Inc. Feb 11 2003 |
Copyright_xml | – notice: 2003 INIST-CNRS – notice: Copyright American Heart Association, Inc. Feb 11 2003 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM K9. NAPCQ U9A 7X8 |
DOI | 10.1161/01.CIR.0000055189.18831.B1 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Career and Technical Education (Alumni Edition) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1524-4539 |
EndPage | 670 |
ExternalDocumentID | 289936411 12578864 14544080 10_1161_01_CIR_0000055189_18831_B1 |
Genre | Journal Article |
GroupedDBID | --- .-D .3C .55 .GJ .XZ .Z2 01R 0R~ 0ZK 18M 1J1 29B 2FS 2WC 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAAV AAAXR AAFWJ AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AARTV AASOK AAUEB AAWTL AAXQO AAYXX ABBUW ABDIG ABJNI ABOCM ABPMR ABPXF ABQRW ABXVJ ABZAD ACCJW ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACOAL ACRKK ACWDW ACWRI ACXNZ ACZKN ADBBV ADCYY ADFPA ADGGA ADHPY ADKSD ADNKB AE3 AE6 AEETU AENEX AFCHL AFDTB AFEXH AFFNX AFNMH AFUWQ AGINI AHMBA AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW ALKUP ALMA_UNASSIGNED_HOLDINGS AMJPA AMNEI ASPBG AVWKF AYCSE AZFZN BAWUL BOYCO BQLVK BS7 BYPQX C1A C45 CITATION CS3 DIK DIWNM DU5 DUNZO E.X E3Z EBS EX3 F2K F2L F2M F2N F5P FCALG FEDTE FL- FW0 GX1 H0~ H13 HVGLF HZ~ H~9 IKREB IKYAY IN~ J5H JF9 JG8 JK3 JK8 K-A K-F K8S KD2 KMI KQ8 L-C L7B M18 N4W N9A NEJ N~7 N~B N~M O9- OAG OAH OBH OCB OCUKA ODA ODMTH OGEVE OHH OHT OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P2P PQQKQ R58 RAH RLZ S4R S4S T8P TEORI TR2 UPT V2I VVN W2D W3M W8F WH7 WHG WOQ WOW X3V X3W X7M XXN XYM YFH YOC YSK YYM YYP YZZ ZFV ZGI ZXP ZY1 ZZMQN ~H1 1CY 41~ AAEJM AAQKA AASCR AASXQ ABASU ABVCZ ABXYN ABZZY ACLDA ACXJB AEBDS AFBFQ AFMBP AFSOK AHQVU AJJEV AKCTQ AKULP ALMTX AMKUR AOHHW AOQMC EEVPB EJD ERAAH GNXGY GQDEL HLJTE IPNFZ IQODW MVM P-K RIG TSPGW YQJ YXB AAYOK ACIJW AWKKM CGR CUY CVF ECM EIF NPM OJAPA OLW PKN RHF K9. NAPCQ U9A 7X8 |
ID | FETCH-LOGICAL-c413t-bb03179f2146674263fc2f5d3947d96d46094ce0c41338b38727ba869e554e623 |
ISSN | 0009-7322 1524-4539 |
IngestDate | Mon Sep 08 11:51:57 EDT 2025 Fri Jul 25 03:39:20 EDT 2025 Wed Feb 19 02:32:06 EST 2025 Mon Jul 21 09:17:22 EDT 2025 Thu Apr 24 23:08:50 EDT 2025 Wed Oct 01 02:48:26 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Human Nervous system diseases risk factors Enzyme Stenosis Cardiovascular disease Genetic determinism Thrombosis Cerebral disorder Factor VII Arterial disease Vascular disease Peptidases Carotid Central nervous system disease Atherosclerosis Risk factor thrombolysis Hydrolases Cerebrovascular disease Polymorphism |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c413t-bb03179f2146674263fc2f5d3947d96d46094ce0c41338b38727ba869e554e623 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 12578864 |
PQID | 212750868 |
PQPubID | 24119 |
PageCount | 4 |
ParticipantIDs | proquest_miscellaneous_73007226 proquest_journals_212750868 pubmed_primary_12578864 pascalfrancis_primary_14544080 crossref_primary_10_1161_01_CIR_0000055189_18831_B1 crossref_citationtrail_10_1161_01_CIR_0000055189_18831_B1 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2003-02-11 |
PublicationDateYYYYMMDD | 2003-02-11 |
PublicationDate_xml | – month: 02 year: 2003 text: 2003-02-11 day: 11 |
PublicationDecade | 2000 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: United States – name: Baltimore |
PublicationTitle | Circulation (New York, N.Y.) |
PublicationTitleAlternate | Circulation |
PublicationYear | 2003 |
Publisher | Lippincott Williams & Wilkins American Heart Association, Inc |
Publisher_xml | – name: Lippincott Williams & Wilkins – name: American Heart Association, Inc |
References | e_1_3_2_9_2 e_1_3_2_8_2 e_1_3_2_7_2 e_1_3_2_1_2 (e_1_3_2_6_2) 2001; 12 e_1_3_2_10_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_2_2 (e_1_3_2_3_2) 1999; 76 12578860 - Circulation. 2003 Feb 11;107(5):654-5 |
References_xml | – ident: e_1_3_2_2_2 doi: 10.1093/oxfordjournals.jbchem.a021861 – ident: e_1_3_2_12_2 doi: 10.1182/blood.V96.5.1820 – volume: 12 start-page: 376 year: 2001 ident: e_1_3_2_6_2 publication-title: Blood Coag Fibrinol – ident: e_1_3_2_8_2 doi: 10.1161/atvb.19.6.1491 – ident: e_1_3_2_5_2 doi: 10.1097/00001721-200201000-00001 – ident: e_1_3_2_10_2 – ident: e_1_3_2_1_2 doi: 10.1093/oxfordjournals.jbchem.a021362 – ident: e_1_3_2_11_2 doi: 10.1055/s-0037-1614949 – volume: 76 start-page: 292 year: 1999 ident: e_1_3_2_3_2 publication-title: Haemostasis – ident: e_1_3_2_9_2 doi: 10.1161/atvb.20.2.529 – ident: e_1_3_2_4_2 doi: 10.1515/BC.2002.121 – ident: e_1_3_2_7_2 doi: 10.1161/atvb.19.6.1484 – reference: 12578860 - Circulation. 2003 Feb 11;107(5):654-5 |
SSID | ssj0006375 |
Score | 2.064461 |
Snippet | Background—
Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the... Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine... BACKGROUND: Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 667 |
SubjectTerms | Adult Aged Biological and medical sciences Carotid Stenosis - diagnostic imaging Carotid Stenosis - epidemiology Carotid Stenosis - genetics Cohort Studies Disease Progression DNA Mutational Analysis Enzyme Activation - genetics Female Follow-Up Studies Gene Frequency Heterozygote Homozygote Humans Italy - epidemiology Male Medical sciences Middle Aged Neurology Odds Ratio Polymorphism, Genetic Predictive Value of Tests Prospective Studies Risk Assessment Risk Factors Serine Endopeptidases - genetics Ultrasonography Urokinase-Type Plasminogen Activator - metabolism Vascular diseases and vascular malformations of the nervous system |
Subtitle | A Prominent Risk Predictor of Carotid Stenosis |
Title | Marburg I Polymorphism of Factor VII–Activating Protease |
URI | https://www.ncbi.nlm.nih.gov/pubmed/12578864 https://www.proquest.com/docview/212750868 https://www.proquest.com/docview/73007226 |
Volume | 107 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1524-4539 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006375 issn: 0009-7322 databaseCode: KQ8 dateStart: 19500101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1524-4539 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0006375 issn: 0009-7322 databaseCode: DIK dateStart: 19500101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1524-4539 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0006375 issn: 0009-7322 databaseCode: GX1 dateStart: 19500101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBASQrDBKIPhB7SXKqX5chLeRtm0wDok1ELfLCdxINKWlDZ9gL-CP5m72PkodGLwEjVuLol8v5zPvvP9CHlpOW4iokAaOJobcMIMUHNkgDNngX-aCLPiIphcsLOZ827uznu9n52spXUZDeMfW_eV_I9WoQ30irtk_0GzzU2hAX6DfuEIGobjjXQ8EdgnXwYhci3AJB76DDkvwP9TNDqDT2FoGLh1ARdeq23nRYnxGLXFGc6uwMnMS5Vgvlhi0AbFMNVcwKVZMgAQ5MUqW3Wd2HG2jDXr1zYyn87iAq7myKzUOb8i74T8Zfz1UqeZpS1CP8tM07l0MpeqBfNMsW4vYYjcWKnA-LChLak2rpYDcFDFi4ZyS1ttkRURroae27GvTHF3_Gn3mVntZRjG2VKVpMRKc8HQ9H3bHEZmO9rVEf6LD_x0dn7Opyfz6dHim4E8ZBiv16Qst8hty2MMOTHehu-bsZ3ZVenm5q11GVt4_KvrH77h8txbiBV8famiTbl-XlP5N9MH5L6emNBjhbKHpCfzXbJ3nIuyuPpOj2iVKlzFYHbJnYnOyNgjmcYgDWkXg7RIqcIg_Q2DtMbgaypog0CKCKQNAlFcI5DWCHxEZqcn0_GZoek7jBg8o9KIIhgwvCBF6njmITFAGlupm9iB4yUBSxw2CpxYjvBq249sH1zpSPgskODiSnDLH5OdvMjlE0JjsHfCDvxY-uCOBiCXCitynXjkS8uJvD4J6h7msa5tjxQrl7ya4zKTj0w-Dj_yVju80g5_Y_aJ3cguVIWXG0kdbiiyFXVcJHEf9clBrVmuTcaKKzoFn_l98qL5F-w5BulELov1iiN_hAd2sk_2FRzaO-Po6jPn6V9lD8jd9vt7RnbK5Vo-B9-5jA4rOP8CfX--nA |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Marburg+I+polymorphism+of+factor+VII--activating+protease%3A+a+prominent+risk+predictor+of+carotid+stenosis&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Willeit%2C+Johann&rft.au=Kiechl%2C+Stefan&rft.au=Weimer%2C+Thomas&rft.au=Mair%2C+Artur&rft.date=2003-02-11&rft.issn=1524-4539&rft.eissn=1524-4539&rft.volume=107&rft.issue=5&rft.spage=667&rft_id=info:doi/10.1161%2F01.cir.0000055189.18831.b1&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon |